115 related articles for article (PubMed ID: 11438909)
1. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.
Duong M; Piroth L; Peytavin G; Forte F; Kohli E; Grappin M; Buisson M; Chavanet P; Portier H
Clin Infect Dis; 2001 Aug; 33(3):386-92. PubMed ID: 11438909
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
Yasuda JM; Miller C; Currier JS; Forthal DN; Kemper CA; Beall GN; Tilles JG; Capparelli EV; McCutchan JA; Haubrich RH;
Antivir Ther; 2004 Oct; 9(5):753-61. PubMed ID: 15535413
[TBL] [Abstract][Full Text] [Related]
4. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
6. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients.
Casado JL; Sabido R; Perez-Elías MJ; Antela A; Oliva J; Dronda F; Mejía B; Fortún J
Antivir Ther; 1999; 4(3):157-61. PubMed ID: 12731755
[TBL] [Abstract][Full Text] [Related]
7. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic.
McNabb J; Ross JW; Abriola K; Turley C; Nightingale CH; Nicolau DP
Clin Infect Dis; 2001 Sep; 33(5):700-5. PubMed ID: 11486292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.
Piketty C; Weiss L; Thomas F; Mohamed AS; Belec L; Kazatchkine MD
J Infect Dis; 2001 May; 183(9):1328-35. PubMed ID: 11294663
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
11. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.
Le Moing V; Thiébaut R; Chêne G; Leport C; Cailleton V; Michelet C; Fleury H; Herson S; Raffi F;
J Infect Dis; 2002 Feb; 185(4):471-80. PubMed ID: 11865399
[TBL] [Abstract][Full Text] [Related]
12. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
14. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.
Wood E; Hogg RS; Yip B; Quercia R; Harrigan PR; O'Shaughnessy MV; Montaner JS
J Infect Dis; 2003 Nov; 188(10):1421-5. PubMed ID: 14624366
[TBL] [Abstract][Full Text] [Related]
15. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
Duong M; Buisson M; Peytavin G; Kohli E; Piroth L; Martha B; Grappin M; Chavanet P; Portier H
Ann Pharmacother; 2005 Apr; 39(4):603-9. PubMed ID: 15713788
[TBL] [Abstract][Full Text] [Related]
16. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
18. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
19. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
